StreetInsider
Log in to your account:
Log in
Signup
Home
EPS Insider
Event Calendar
Conferences
Classic Site
Upgrade to SI Premium - Free Trial
Gilead (GILD) Receives Updated CHMP Recommendations on Zydelig as CLL, Follicular Lymphoma Treatment
July 22, 2016 7:19 AM
The CHMP (EMA’s Committee for Medicinal Products for Human Use) has confirmed that the benefits of Gilead's (Nasdaq: GILD) Zydelig ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
Categories
Corporate News
Next Articles
Jefferies Remains Sidelined on Gilead Sciences (GILD) Following 2Q - PT to $93
July 26, 2016 9:15 AM
European CHMP Adopts Positive Opinion on Gilead’s Type II Variation Application for Truvada® for Reducing the Risk of Sexually Acquired HIV
July 22, 2016 7:17 AM
Gilead Sciences (GILD) Receives Positive CHMP Opinion on Updated Truvada Marketing Terms
July 22, 2016 7:13 AM
Gilead Sciences (GILD) Announces Two Odefsey Phase 3b Studies Met Primary Objectives
July 21, 2016 4:33 PM
